Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan

  • Shingo Fukuma
    Correspondence
    Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: [email protected]
    Affiliations
    Department of Healthcare Epidemiology, School of Public Health at Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan

    Institute for Health Outcomes and Process Evaluation Research (iHope International), Tokyo, Japan
    Search for articles by this author
  • Noriaki Kurita
    Affiliations
    Department of Healthcare Epidemiology, School of Public Health at Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Institute for Health Outcomes and Process Evaluation Research (iHope International), Tokyo, Japan
    Search for articles by this author
  • Masafumi Fukagawa
    Affiliations
    Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan
    Search for articles by this author
  • Tadao Akizawa
    Affiliations
    Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
    Search for articles by this author
  • Shunichi Fukuhara
    Affiliations
    Department of Healthcare Epidemiology, School of Public Health at Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Fukushima Medical University, Fukushima, Japan
    Search for articles by this author
      Chronic kidney disease-mineral and bone disorder (CKD-MBD) has recently attracted attention in light of its association with clinical outcomes, such as fracture, cardiovascular disease, and mortality. Management of CKD-MBD has therefore come to have a central role in dialysis practice. Cinacalcet, a newly developed drug, has changed prescription patterns in many centers based on different changes in MBD markers than those observed with active vitamin D derivatives. As physicians require real-world evidence to guide their treatment decisions with respect to MBD management, we conducted the Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients (MBD-5D), a 3-year observational study involving prevalent hemodialysis patients with secondary hyperparathyroidism (SHPT). Here, we review the results from the MBD-5D and discuss issues of MBD management in the cinacalcet era. Three years since the introduction of cinacalcet, 40% of hemodialysis patients with SHPT have come to use cinacalcet, enjoying marked improvement in management of circulating MBD markers, such as intact parathyroid hormone (PTH), phosphorus, and calcium. Combination therapy with cinacalcet and a vitamin D receptor activator (VDRA) may allow physicians to choose more suitable prescription patterns based on patient characteristics and therapeutic purposes. We observed an additive association between ‘starting cinacalcet’ and ‘increased VDRA dose,’ with marked improvement in the control of intact PTH levels. Further, the combination pattern of ‘starting cinacalcet’ and ‘decreased VDRA dose’ was associated with better achievement of target serum phosphorus and calcium levels. Future studies should examine the effect of different prescription patterns for SHPT treatment on clinical outcomes.

      Keywords

      To read this article in full you will need to make a payment
      ISN Member Login
      ISN Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Block G.A.
        • Klassen P.S.
        • Lazarus J.M.
        • et al.
        Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
        J Am Soc Nephrol. 2004; 15: 2208-2218
        • Investigators E.T.
        • Chertow G.M.
        • Block G.A.
        • et al.
        Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
        N Engl J Med. 2012; 367: 2482-2494
        • Block G.A.
        • Martin K.J.
        • de Francisco A.L.
        • et al.
        Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
        N Engl J Med. 2004; 350: 1516-1525
        • Fukuhara S.
        • Akizawa T.
        • Fukagawa M.
        • et al.
        Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: rationale and study design.
        Ther Apher Dial. 2011; 15: 169-175
        • Yokoyama K.
        • Fukuhara S.
        • Fukagawa M.
        • et al.
        Results of the survey on practice patterns including MBD management at dialysis facilities: as part of the MBD-5D.
        J Jpn Soc Dial Ther. 2011; 44 (Japanese): 557-566
        • Bradbury B.D.
        • Brookhart M.A.
        • Winkelmayer W.C.
        • et al.
        Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations.
        Am J Kidney Dis. 2009; 54: 554-560
        • Fukagawa M.
        • Fukuma S.
        • Onishi Y.
        • et al.
        Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
        Clin J Am Soc Nephrol. 2012; 7: 1473-1480
        • Fukagawa M.
        • Komaba H.
        • Onishi Y.
        • et al.
        Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.
        Am J Nephrol. 2011; 33: 427-437
        • Tentori F.
        • Blayney M.J.
        • Albert J.M.
        • et al.
        Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
        Am J Kidney Dis. 2008; 52: 519-530
        • Tentori F.
        • Albert J.M.
        • Young E.W.
        • et al.
        The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study.
        Nephrol Dial Transplant. 2009; 24: 963-972